摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(2-methyl-2-phenylpropyl)-1,2-benzoxazol-3-amine | 1616343-56-6

中文名称
——
中文别名
——
英文名称
N-(2-methyl-2-phenylpropyl)-1,2-benzoxazol-3-amine
英文别名
——
N-(2-methyl-2-phenylpropyl)-1,2-benzoxazol-3-amine化学式
CAS
1616343-56-6
化学式
C17H18N2O
mdl
——
分子量
266.343
InChiKey
GTSKFZRBVBRULH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.9
  • 重原子数:
    20
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.24
  • 拓扑面积:
    38.1
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为产物:
    参考文献:
    名称:
    Design, synthesis and evaluation of phenethylaminoheterocycles as Kv1.5 inhibitors
    摘要:
    Phenethylaminoheterocycles have been prepared and assayed for inhibition of the K(v)1.5 potassium ion channel as a potential approach to the treatment of atrial fibrillation. A diverse set of heterocycles were identified as potent K(v)1.5 inhibitors and were advanced to pharmacodynamic evaluation based on selectivity and pharmacokinetic profile. Heterocycle optimization and template modification lead to the identification of compound 24 which demonstrated increased atrial effective refractory period in the rabbit pharmacodynamic model with mild effects on blood pressure and heart rate. (C) 2014 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2014.05.035
点击查看最新优质反应信息

文献信息

  • Design, synthesis and evaluation of phenethylaminoheterocycles as Kv1.5 inhibitors
    作者:James A. Johnson、Ningning Xu、Yoon Jeon、Heather J. Finlay、Alexander Kover、Mary L. Conder、Huabin Sun、Danshi Li、Paul Levesque、Mei-Mann Hsueh、Timothy W. Harper、Ruth R. Wexler、John Lloyd
    DOI:10.1016/j.bmcl.2014.05.035
    日期:2014.7
    Phenethylaminoheterocycles have been prepared and assayed for inhibition of the K(v)1.5 potassium ion channel as a potential approach to the treatment of atrial fibrillation. A diverse set of heterocycles were identified as potent K(v)1.5 inhibitors and were advanced to pharmacodynamic evaluation based on selectivity and pharmacokinetic profile. Heterocycle optimization and template modification lead to the identification of compound 24 which demonstrated increased atrial effective refractory period in the rabbit pharmacodynamic model with mild effects on blood pressure and heart rate. (C) 2014 Elsevier Ltd. All rights reserved.
查看更多

同类化合物

苯并异恶唑Hsp90抑制剂 苯并[d]异噁唑-7-醇 苯并[d]异噁唑-5-胺 苯并[d]异噁唑-5-磺酰氯 苯并[D]异恶唑-3-甲酸 苯[D]异恶唑-3-醇 羟基伊洛哌酮 甲基6-氨基-1,2-苯并恶唑-3-羧酸酯 环己酮,2,3-二甲基-6-(1-甲基乙基)-,[2R-(2α,3ba,6ba)]-(9CI) 帕潘立酮杂质1 奈氟齐特 四氢-4-[[[4-[[[4-[[(3R)-四氢-3-呋喃基]氧基]-1,2-苯并恶唑-3-基]氧基]甲基]-1-哌啶基]甲基]-2H-吡喃-4-醇 唑尼酰胺-d4 唑尼沙胺钠 唑尼沙胺13C2-15N 唑尼沙胺 呋喃并[3,4:3,4]环丁二烯并[1,2:3,4]环丁二烯并[1,2-d]异噻唑(9CI) 呋喃并[3,4-f][1,2]苯并恶唑 呋喃并[3,4-e][1,2]苯并恶唑 呋喃并[3,2-g][1,2]苯并恶唑 呋喃并[3,2-f]-1,2-苯并异恶唑 呋喃并[2,3-f][1,2]苯并恶唑 呋喃并[2,3-e][1,2]苯并恶唑 叔-丁基(6-溴苯并[D]异噻唑-3-基)氨基甲酯 化合物 T29498 佐尼氯唑 伊潘立酮(R)-羟基杂质 alpha-甲基-3-苯基-1,2-苯并异恶唑-7-乙酸 [1,2]恶唑并[5,4-f][1,2]苯并恶唑 [1,2]恶唑并[5,4-e][2,1,3]苯并恶二唑 [1,1'-联苯基]-3-醇,2'-(5-乙基-3,4-二苯基-1H-吡唑-1-基)- [(3-氨基-1,2-苯并异恶唑-5-基)甲基]氨基甲酸叔丁酯 N,N-二甲基唑尼沙胺杂质 N-甲氧基-N-甲基苯并[d]异恶唑-3-甲酰胺 N-甲基唑尼沙胺 N-乙基苯异恶唑酮四氟硼酸盐 N-[(1,2-苯并恶唑-3-基甲基)磺酰基]乙酰胺 N-(苯并[D]异恶唑-3-基氧基-二甲基氨基-磷酰)-N-甲基-甲胺 N-(6-己酸)唑尼沙胺 7-硝基-1,2-苯并恶唑 7-甲氧基-3-甲基-1,2-苯并恶唑 7-甲基苯并[d]异恶唑-3-醇 7-溴苯并[d]异噁唑 7-溴苯并[D]异恶唑-3(2H)-酮 7-溴-3-氯苯并[D]异恶唑 7-溴-1,2-苯并恶唑-3-胺 7-氯-苯并[d]异恶唑 7-氟苯并[d]异噁唑-3-胺 7-氟-苯并[d]异噁唑-3-醇 6-苯基苯并[d]异噁唑-3-胺